NO320119B1 - Benmorfogenetisk protein-11 (BMP-11), DNA-molekyl som koder for dette, samt vektorer og vertceller inneholdende DNA-molekylet og fremgangsmate for fremstilling av BMP-11. - Google Patents

Benmorfogenetisk protein-11 (BMP-11), DNA-molekyl som koder for dette, samt vektorer og vertceller inneholdende DNA-molekylet og fremgangsmate for fremstilling av BMP-11. Download PDF

Info

Publication number: NO320119B1
Authority: NO; Norway
Prior art keywords: bmp; seq; protein; sequence; dna
Prior art date: 1993-05-12

Application number

NO19954492A

Other languages

English (en)

Norwegian (no)

Other versions

NO954492D0 (no

NO954492L (no

Inventor

John M Wozney

Anthony J Celeste

Original Assignee

Inst Genetics Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-12

Filing date

1995-11-08

Publication date

2005-10-31

1995-11-08 Application filed by Inst Genetics Llc filed Critical Inst Genetics Llc

1995-11-08 Publication of NO954492D0 publication Critical patent/NO954492D0/no

1995-11-08 Publication of NO954492L publication Critical patent/NO954492L/no

2005-10-31 Publication of NO320119B1 publication Critical patent/NO320119B1/no

Links

108020004414 DNA Proteins 0.000 title claims description 42
238000000034 method Methods 0.000 title claims description 39
239000013598 vector Substances 0.000 title claims description 28
102000053602 DNA Human genes 0.000 title claims description 9
230000008569 process Effects 0.000 title claims description 4
102100040898 Growth/differentiation factor 11 Human genes 0.000 title 3
101710194452 Growth/differentiation factor 11 Proteins 0.000 title 3
108090000623 proteins and genes Proteins 0.000 claims description 177
102000004169 proteins and genes Human genes 0.000 claims description 166
210000004027 cell Anatomy 0.000 claims description 83
108091028043 Nucleic acid sequence Proteins 0.000 claims description 73
239000002773 nucleotide Substances 0.000 claims description 64
125000003729 nucleotide group Chemical group 0.000 claims description 64
108090000765 processed proteins & peptides Proteins 0.000 claims description 43
210000000988 bone and bone Anatomy 0.000 claims description 42
150000001413 amino acids Chemical class 0.000 claims description 39
230000000694 effects Effects 0.000 claims description 36
229920001184 polypeptide Polymers 0.000 claims description 35
102000004196 processed proteins & peptides Human genes 0.000 claims description 35
125000003275 alpha amino acid group Chemical group 0.000 claims description 29
230000014509 gene expression Effects 0.000 claims description 28
238000004519 manufacturing process Methods 0.000 claims description 21
108091026890 Coding region Proteins 0.000 claims description 15
230000000921 morphogenic effect Effects 0.000 claims description 14
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 11
102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 11
108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims description 10
102100028728 Bone morphogenetic protein 1 Human genes 0.000 claims description 10
210000004962 mammalian cell Anatomy 0.000 claims description 10
239000000539 dimer Substances 0.000 claims description 9
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 8
102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 8
239000001963 growth medium Substances 0.000 claims description 8
238000000746 purification Methods 0.000 claims description 8
108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 7
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 7
102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 7
108020004705 Codon Proteins 0.000 claims description 7
102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 6
101710118482 Bone morphogenetic protein 10 Proteins 0.000 claims description 6
230000004071 biological effect Effects 0.000 claims description 6
108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 claims description 5
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 5
102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 5
102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims description 5
101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 claims description 5
230000003412 degenerative effect Effects 0.000 claims description 5
238000002955 isolation Methods 0.000 claims description 3
102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 155
239000000203 mixture Substances 0.000 description 40
101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 37
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 36
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 36
235000001014 amino acid Nutrition 0.000 description 36
229940028334 follicle stimulating hormone Drugs 0.000 description 36
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 34
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 34
229940024606 amino acid Drugs 0.000 description 34
241000283690 Bos taurus Species 0.000 description 30
210000000845 cartilage Anatomy 0.000 description 19
239000002299 complementary DNA Substances 0.000 description 18
239000000523 sample Substances 0.000 description 18
229940112869 bone morphogenetic protein Drugs 0.000 description 16
239000013615 primer Substances 0.000 description 16
241001515965 unidentified phage Species 0.000 description 16
239000012634 fragment Substances 0.000 description 15
101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 14
238000003556 assay Methods 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
108010004250 Inhibins Proteins 0.000 description 13
102000002746 Inhibins Human genes 0.000 description 13
108010059616 Activins Proteins 0.000 description 12
239000000020 Nitrocellulose Substances 0.000 description 11
230000003321 amplification Effects 0.000 description 11
239000000893 inhibin Substances 0.000 description 11
229920001220 nitrocellulos Polymers 0.000 description 11
238000003199 nucleic acid amplification method Methods 0.000 description 11
230000001580 bacterial effect Effects 0.000 description 10
210000002808 connective tissue Anatomy 0.000 description 10
239000003102 growth factor Substances 0.000 description 10
108010067479 inhibin B Proteins 0.000 description 10
239000000463 material Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 10
102100026818 Inhibin beta E chain Human genes 0.000 description 9
241000700159 Rattus Species 0.000 description 9
108010022394 Threonine synthase Proteins 0.000 description 9
239000000488 activin Substances 0.000 description 9
102000004419 dihydrofolate reductase Human genes 0.000 description 9
239000007943 implant Substances 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
230000013595 glycosylation Effects 0.000 description 8
238000006206 glycosylation reaction Methods 0.000 description 8
239000000833 heterodimer Substances 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
230000001939 inductive effect Effects 0.000 description 8
239000011159 matrix material Substances 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
230000011164 ossification Effects 0.000 description 8
230000001817 pituitary effect Effects 0.000 description 8
239000002243 precursor Substances 0.000 description 8
241000701161 unidentified adenovirus Species 0.000 description 8
102000018233 Fibroblast Growth Factor Human genes 0.000 description 7
108050007372 Fibroblast Growth Factor Proteins 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
102000004067 Osteocalcin Human genes 0.000 description 7
108090000573 Osteocalcin Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
229940126864 fibroblast growth factor Drugs 0.000 description 7
102000057639 human GDF11 Human genes 0.000 description 7
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
238000012545 processing Methods 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
238000010561 standard procedure Methods 0.000 description 7
102000008154 Bone Morphogenetic Protein 6 Human genes 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 6
102100040892 Growth/differentiation factor 2 Human genes 0.000 description 6
102100032352 Leukemia inhibitory factor Human genes 0.000 description 6
230000035558 fertility Effects 0.000 description 6
239000000710 homodimer Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
230000029663 wound healing Effects 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
102000014429 Insulin-like growth factor Human genes 0.000 description 5
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
102000003982 Parathyroid hormone Human genes 0.000 description 5
108090000445 Parathyroid hormone Proteins 0.000 description 5
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
206010052428 Wound Diseases 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
238000004166 bioassay Methods 0.000 description 5
230000022159 cartilage development Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000029087 digestion Effects 0.000 description 5
239000012894 fetal calf serum Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
229960000485 methotrexate Drugs 0.000 description 5
239000000199 parathyroid hormone Substances 0.000 description 5
229960001319 parathyroid hormone Drugs 0.000 description 5
230000010076 replication Effects 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
230000017423 tissue regeneration Effects 0.000 description 5
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
239000003155 DNA primer Substances 0.000 description 4
230000006820 DNA synthesis Effects 0.000 description 4
101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 4
108090000144 Human Proteins Proteins 0.000 description 4
102000003839 Human Proteins Human genes 0.000 description 4
101001060271 Mus musculus Fibroblast growth factor 4 Proteins 0.000 description 4
101001098398 Mus musculus Osteocalcin Proteins 0.000 description 4
108020005187 Oligonucleotide Probes Proteins 0.000 description 4
102000009618 Transforming Growth Factors Human genes 0.000 description 4
108010009583 Transforming Growth Factors Proteins 0.000 description 4
241000700605 Viruses Species 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
239000000356 contaminant Substances 0.000 description 4
238000012258 culturing Methods 0.000 description 4
230000007547 defect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
239000002751 oligonucleotide probe Substances 0.000 description 4
230000008439 repair process Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 3
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
102000005606 Activins Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
241000283707 Capra Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
238000010276 construction Methods 0.000 description 3
239000003433 contraceptive agent Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
229910052588 hydroxylapatite Inorganic materials 0.000 description 3
230000006698 induction Effects 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
241001131785 Escherichia coli HB101 Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
102000002067 Protein Subunits Human genes 0.000 description 2
108010001267 Protein Subunits Proteins 0.000 description 2
108020005067 RNA Splice Sites Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
239000013602 bacteriophage vector Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004271 bone marrow stromal cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
229940124558 contraceptive agent Drugs 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000002710 gonadal effect Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
244000144972 livestock Species 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
230000006576 neuronal survival Effects 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
230000002188 osteogenic effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
208000028169 periodontal disease Diseases 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000037452 priming Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
241000894007 species Species 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000002435 tendon Anatomy 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
235000019731 tricalcium phosphate Nutrition 0.000 description 2
229940078499 tricalcium phosphate Drugs 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000003044 Closed Fractures Diseases 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000710188 Encephalomyocarditis virus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100040895 Growth/differentiation factor 10 Human genes 0.000 description 1
101710194458 Growth/differentiation factor 10 Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000836430 Hilda Species 0.000 description 1
101000695352 Homo sapiens Bone morphogenetic protein 1 Proteins 0.000 description 1
101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
102100025885 Inhibin alpha chain Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101710113100 Membrane-bound alkaline phosphatase Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101710167839 Morphogenetic protein Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
208000002565 Open Fractures Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
108010023082 activin A Proteins 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
150000004645 aluminates Chemical class 0.000 description 1
210000004198 anterior pituitary gland Anatomy 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000003462 bioceramic Substances 0.000 description 1
239000005312 bioglass Substances 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
230000014461 bone development Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
108010046910 brain-derived growth factor Proteins 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000003321 cartilage cell Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
230000000913 erythropoietic effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000001733 follicular fluid Anatomy 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000009650 gentamicin protection assay Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
102000046095 human BMP6 Human genes 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
108010032856 inhibin-alpha subunit Proteins 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000013289 male long evans rat Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
230000002138 osteoinductive effect Effects 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000002943 spectrophotometric absorbance Methods 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002381 testicular Effects 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)

NO19954492A 1993-05-12 1995-11-08 Benmorfogenetisk protein-11 (BMP-11), DNA-molekyl som koder for dette, samt vektorer og vertceller inneholdende DNA-molekylet og fremgangsmate for fremstilling av BMP-11. NO320119B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6146493A	1993-05-12	1993-05-12
PCT/US1994/005288 WO1994026892A1 (fr)	1993-05-12	1994-05-12	Compositions de bmp-11

Publications (3)

Publication Number	Publication Date
NO954492D0 NO954492D0 (no)	1995-11-08
NO954492L NO954492L (no)	1995-11-08
NO320119B1 true NO320119B1 (no)	2005-10-31

Family

ID=22035966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19954492A NO320119B1 (no)	1993-05-12	1995-11-08	Benmorfogenetisk protein-11 (BMP-11), DNA-molekyl som koder for dette, samt vektorer og vertceller inneholdende DNA-molekylet og fremgangsmate for fremstilling av BMP-11.

Country Status (16)

Country	Link
US (7)	US5639638A (fr)
EP (4)	EP0698094B1 (fr)
JP (2)	JP3681069B2 (fr)
KR (1)	KR100227406B1 (fr)
AT (2)	ATE258984T1 (fr)
AU (1)	AU678582B2 (fr)
BR (1)	BR9406715A (fr)
CA (1)	CA2161808C (fr)
DE (2)	DE69434875T2 (fr)
DK (2)	DK1378572T3 (fr)
ES (2)	ES2274157T3 (fr)
FI (1)	FI119696B (fr)
NO (1)	NO320119B1 (fr)
OA (1)	OA10191A (fr)
PT (2)	PT1378572E (fr)
WO (1)	WO1994026892A1 (fr)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE20004692U1 (de)	2000-03-14	2001-07-26	Sofamor Danek GmbH, 94469 Deggendorf	Wirbelimplantat zum Einschrauben in einen Wirbelzwischenraum
US6150328A (en)	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
US20080139474A1 (en) *	1991-11-04	2008-06-12	David Israel	Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
WO1993009229A1 (fr)	1991-11-04	1993-05-13	Genetics Institute, Inc.	Proteines heterodimeres morphogenetiques d'os de recombinaison, compositions et procedes d'utilisation
US7393682B1 (en) *	1993-03-19	2008-07-01	The Johns Hopkins University School Of Medicine	Polynucleotides encoding promyostatin polypeptides
US20030074680A1 (en) *	1993-03-19	2003-04-17	Johns Hopkins University School Of Medicine	Growth differentiation factor-8
US6465239B1 (en) *	1993-03-19	2002-10-15	The John Hopkins University School Of Medicine	Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
WO1994026892A1 (fr) *	1993-05-12	1994-11-24	Genetics Institute, Inc.	Compositions de bmp-11
US6291206B1 (en)	1993-09-17	2001-09-18	Genetics Institute, Inc.	BMP receptor proteins
AU689184B2 (en)	1993-12-07	1998-03-26	Genetics Institute, Llc	BMP-12, BMP-13 and tendon-inducing compositions thereof
US5942496A (en)	1994-02-18	1999-08-24	The Regent Of The University Of Michigan	Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en)	1994-03-15	2003-04-22	University Of Birmingham	Compositions and methods for delivery of agents for neuronal regeneration and survival
US7332575B2 (en) *	1994-03-18	2008-02-19	The Johns Hopkins University School Of Medicine	Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US5906827A (en) *	1994-06-03	1999-05-25	Creative Biomolecules, Inc.	Matrix for the manufacture of autogenous replacement body parts
US20030167492A1 (en) *	1994-07-08	2003-09-04	Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
EP1574577A3 (fr) *	1994-07-08	2006-06-14	The Johns Hopkins University School Of Medicine	Facteur 11 de differentation de croissance
US6008434A (en)	1994-07-08	1999-12-28	Johns Hopkins University School Of Medicine	Growth differentiation factor-11 transgenic mice
US5846770A (en) *	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
US5645084A (en) *	1995-06-07	1997-07-08	Danek Medical, Inc.	Method for spinal fusion without decortication
US5635372A (en) *	1995-05-18	1997-06-03	Genetics Institute, Inc.	BMP-15 compositions
EP1364656B1 (fr)	1995-06-05	2013-11-20	Genetics Institute, LLC	Utilisation de protéines morphogéniques osseuses pour soigner et réparer les insertions du tissu conjonctif
US5902785A (en) *	1995-06-06	1999-05-11	Genetics Institute, Inc.	Cartilage induction by bone morphogenetic proteins
US5700774A (en) *	1996-03-26	1997-12-23	Genetics Institute, Inc.	Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
US5965403A (en)	1996-09-18	1999-10-12	Genetics Institute, Inc.	Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US6037519A (en) *	1997-10-20	2000-03-14	Sdgi Holdings, Inc.	Ceramic fusion implants and compositions
EP0973926A1 (fr)	1997-03-14	2000-01-26	Selective Genetics, Inc.	Vecteurs adenoviraux a modification du tropisme
US20010016646A1 (en)	1998-03-20	2001-08-23	David C. Rueger	Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en)	1997-03-20	2006-05-09	Stryker Corporation	Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
WO1998054572A1 (fr)	1997-05-30	1998-12-03	Creative Biomolecules, Inc.	Procedes pour evaluer la morphogenese des tissus et leur activite
US5972368A (en)	1997-06-11	1999-10-26	Sdgi Holdings, Inc.	Bone graft composites and spacers
US7923250B2 (en)	1997-07-30	2011-04-12	Warsaw Orthopedic, Inc.	Methods of expressing LIM mineralization protein in non-osseous cells
ES2320603T3 (es)	1997-07-30	2009-05-25	Emory University	Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US6696260B1 (en) *	1997-08-01	2004-02-24	The Johns Hopkins University School Of Medicine	Methods to identify growth differentiation factor (GDF) binding proteins
AU8666398A (en) *	1997-08-01	1999-02-22	Johns Hopkins University School Of Medicine, The	Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) *	1997-08-01	2005-05-10	The Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a truncated activintype II receptor
US20020052026A1 (en)	1997-10-08	2002-05-02	Steven M. Vicik	Methods of refolding proteins
US6511509B1 (en)	1997-10-20	2003-01-28	Lifenet	Textured bone allograft, method of making and using same
WO1999024057A2 (fr) *	1997-11-07	1999-05-20	Genetics Inst	Utilisations neuronales de bmp-11
US6027917A (en)	1997-12-10	2000-02-22	Genetics Institute, Inc.	Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
US20030036629A1 (en) *	1997-12-12	2003-02-20	Barry Foster	Novel tgf-beta protein purification methods
US6004937A (en) *	1998-03-09	1999-12-21	Genetics Institute, Inc.	Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US7147839B2 (en)	1998-05-29	2006-12-12	Curis, Inc.	Methods for evaluating tissue morphogenesis and activity
CA2336536A1 (fr) *	1998-07-28	2000-02-10	The Johns Hopkins University School Of Medicine	Facteur 11 de differentiation de croissance
AU5341999A (en)	1998-08-06	2000-02-28	Sdgi Holdings, Inc.	Composited intervertebral bone spacers
US6849255B2 (en) *	1998-08-18	2005-02-01	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Methods and compositions for enhancing cartilage repair
US6727224B1 (en)	1999-02-01	2004-04-27	Genetics Institute, Llc.	Methods and compositions for healing and repair of articular cartilage
AU4676600A (en) *	1999-04-30	2000-11-17	Curis, Inc.	Morphogen-induced enhancement of fertility
DK1223990T3 (da)	1999-10-15	2004-11-29	Inst Genetics Llc	Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner
ES2278648T3 (es)	1999-12-06	2007-08-16	Warsaw Orthopedic, Inc.	Dispositivo para tratar un disco intervertebral.
US20030082233A1 (en) *	2000-12-01	2003-05-01	Lyons Karen M.	Method and composition for modulating bone growth
US6752831B2 (en)	2000-12-08	2004-06-22	Osteotech, Inc.	Biocompatible osteogenic band for repair of spinal disorders
US8758438B2 (en)	2000-12-08	2014-06-24	Warsaw Orthopedic, Inc.	Implant for orthopedic applications
US7141392B2 (en)	2001-01-09	2006-11-28	Queen Mary And Westfield College	Latent fusion protein
US6942853B2 (en) *	2001-01-09	2005-09-13	Queen Mary And Westfield College	Latent fusion protein
EP1790726B1 (fr) *	2001-02-08	2013-07-03	Wyeth LLC	Propeptides GDF modifiés et stabilisés et leur utilisation
TW200526779A (en)	2001-02-08	2005-08-16	Wyeth Corp	Modified and stabilized GDF propeptides and uses thereof
KR100420798B1 (ko) *	2001-02-10	2004-03-02	(주)알에이싸이언스	펩타이드 벡터
US7226587B2 (en)	2001-06-01	2007-06-05	Wyeth	Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en)	2001-06-08	2006-12-01	Wyeth Corp	Calcium phosphate delivery vehicles for osteoinductive proteins
US7320789B2 (en)	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
US6798160B2 (en) *	2001-11-02	2004-09-28	Honda Giken Kogyo Kabushiki Kaisha	Electric working machine
KR100955410B1 (ko) *	2001-11-27	2010-05-06	타키론 가부시기가이샤	임플란트 재료 및 이의 제조방법
CH695985A5 (de) *	2002-01-21	2006-11-15	Straumann Holding Ag	Oberflächenmodifizierte Implantate.
BR0307871A (pt)	2002-02-21	2005-04-12	Wyeth Corp	Proteìnas contendo domìnio de folistatina
EP1572909A4 (fr)	2002-02-21	2007-06-06	Wyeth Corp	Proteine contenant un domaine de follistatine
TWI282283B (en) *	2002-05-17	2007-06-11	Wyeth Corp	Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
US7241740B2 (en)	2002-08-13	2007-07-10	Wyeth	Peptides as solubilizing excipients for transforming growth factor beta proteins
MXPA05002968A (es) *	2002-09-16	2005-09-08	Univ Johns Hopkins	Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es)	2002-10-22	2006-01-18	Wyeth Corp	Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) *	2002-10-25	2004-11-11	Wolfman Neil M.	ActRIIB fusion polypeptides and uses therefor
RU2322261C2 (ru) *	2003-06-02	2008-04-20	Уайт	Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
JP5392981B2 (ja)	2003-09-12	2014-01-22	ワイス・エルエルシー	骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト
ATE478008T1 (de)	2004-03-10	2010-09-15	Scil Technology Gmbh	Überzogene implantate, ihre herstellung und verwendung davon
EP1740609A2 (fr)	2004-04-27	2007-01-10	Research Development Foundation	Antagoniste de signalisation des recepteurs de la superfamille du tgf-beta
CA2567405A1 (fr)	2004-05-25	2005-12-08	Stryker Corporation	Utilisation des proteines morphogeniques pour traiter les anomalies des cartilages
US7749268B2 (en)	2004-05-26	2010-07-06	Warsaw Orthopedic, Inc.	Methods for treating the spine
AU2005272646A1 (en) *	2004-08-12	2006-02-23	Wyeth	Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
US7473678B2 (en)	2004-10-14	2009-01-06	Biomimetic Therapeutics, Inc.	Platelet-derived growth factor compositions and methods of use thereof
WO2006081379A1 (fr) *	2005-01-26	2006-08-03	Wyeth	Utilisation de sfrps, en tant que marqueurs d'une activte bmp
JP2008537777A (ja) *	2005-03-23	2008-09-25	ワイス	Ｇｄｆ−８調節剤に対する免疫応答の検出
EP1863518A2 (fr) *	2005-03-30	2007-12-12	Wyeth	Methodes pour stimuler la pousse des cheveux par administration de proteines bmp
US8506646B2 (en)	2005-04-29	2013-08-13	Warsaw Orthopedic, Inc.	Multi-purpose medical implant devices
US20060247790A1 (en) *	2005-04-30	2006-11-02	Mckay William F	Shaped osteochondral grafts and methods of using same
EP1951756B1 (fr)	2005-10-06	2015-01-07	Eli Lilly And Company	Anticorps anti-myostatine
UA92504C2 (en)	2005-10-12	2010-11-10	Эли Лилли Энд Компани	Anti-myostatin monoclonal antibody
US8147860B2 (en)	2005-12-06	2012-04-03	Etex Corporation	Porous calcium phosphate bone material
ES2443581T3 (es)	2006-02-09	2014-02-19	Biomimetic Therapeutics, Llc	Composiciones y métodos para el tratamiento de hueso
CA2652549A1 (fr)	2006-05-17	2007-12-13	Stryker Corporation	Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble
AU2007269712B2 (en)	2006-06-30	2013-02-07	Biomimetic Therapeutics, Llc	PDGF-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en)	2006-06-30	2015-10-20	Biomimetic Therapeutics, Llc	Compositions and methods for treating the vertebral column
US8524265B2 (en)	2006-08-17	2013-09-03	Warsaw Orthopedic, Inc.	Medical implant sheets useful for tissue regeneration
BRPI0716249A2 (pt)	2006-09-05	2013-09-03	Lilly Co Eli	anticorpos antimiostatina
JP2008104401A (ja) *	2006-10-25	2008-05-08	Kyoto Univ	精原幹細胞のインビトロ増殖方法
AU2007234612B2 (en)	2006-12-14	2013-06-27	Johnson & Johnson Regenerative Therapeutics, Llc	Protein stabilization formulations
AU2007339280B2 (en)	2006-12-21	2013-12-05	Stryker Corporation	Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US7678764B2 (en)	2007-06-29	2010-03-16	Johnson & Johnson Regenerative Therapeutics, Llc	Protein formulations for use at elevated temperatures
JP5323832B2 (ja)	2007-08-07	2013-10-23	アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー	酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
AU2009214629A1 (en)	2008-02-13	2009-08-20	Eric T. Choi	BMP-7 for use in treating vascular sclerosis
BRPI0911048A2 (pt)	2008-04-14	2015-12-29	Atrm Llc	formulações líquidas tamponadas de gdf-5
BR122020000059B8 (pt)	2008-09-09	2021-06-22	Biomimetic Therapeutics Inc	composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
AU2010213575B2 (en)	2009-02-12	2013-11-14	Stryker Corporation	Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
JP5819734B2 (ja)	2009-02-12	2015-11-24	ストライカーコーポレイションＳｔｒｙｋｅｒＣｏｒｐｏｒａｔｉｏｎ	ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法
US20120148539A1 (en)	2009-03-24	2012-06-14	Moulay Hicham Alaoui-Ismaili	Methods and Compositions for Tissue Engineering
US8609127B2 (en)	2009-04-03	2013-12-17	Warsaw Orthopedic, Inc.	Medical implant with bioactive material and method of making the medical implant
WO2010144696A1 (fr)	2009-06-11	2010-12-16	Burnham Institute For Medical Research	Différenciation dirigée de cellules souches
US9399086B2 (en)	2009-07-24	2016-07-26	Warsaw Orthopedic, Inc	Implantable medical devices
WO2011031856A1 (fr)	2009-09-09	2011-03-17	Stryker Corporation	Bmp-7 à utiliser dans le traitement de la douleur induite par les lésions et les maladies d'articulation
CA2774024A1 (fr)	2009-09-17	2011-03-24	Stryker Corporation	Tampons utilises pour la regulation du ph des proteines morphogenetiques osseuses
WO2011087768A1 (fr)	2009-12-22	2011-07-21	Stryker Corporation	Variants de la bmp-7 dotés d'une immunogénicité réduite
BR112012020566B1 (pt)	2010-02-22	2021-09-21	Biomimetic Therapeutics, Llc	Composição de fator de crescimento derivado de plaqueta
WO2011139594A2 (fr)	2010-04-27	2011-11-10	Medtronic, Inc.	Bourse artificielle pour administration de médicament intra-articulaire
CN105198981B (zh)	2010-08-20	2019-07-16	惠氏有限责任公司	经设计的成骨蛋白
US9688735B2 (en)	2010-08-20	2017-06-27	Wyeth Llc	Designer osteogenic proteins
US8998925B2 (en)	2011-06-20	2015-04-07	Rdc Holdings, Llc	Fixation system for orthopedic devices
WO2012177759A1 (fr)	2011-06-20	2012-12-27	Rdc Holdings, Llc	Système et procédé de réparation d'articulations
EP2828289B1 (fr) *	2012-03-19	2020-02-26	The Brigham and Women's Hospital, Inc.	Facteur de différenciation de croissance (gdf) 11 destiné au traitement d'une condition cardiovasculaire liee a l'age
WO2014012101A1 (fr)	2012-07-13	2014-01-16	Trustees Of Tufts College	Compactage de poudre de soie pour fabrication de constructions à résistance mécanique et rigidité élevées
US20160120945A1 (en) *	2013-02-15	2016-05-05	The Brigham And Women's Hospital, Inc.	Thymic Regeneration
ES2924479T3 (es) *	2013-04-08	2022-10-07	Harvard College	Composiciones para rejuvenecer las células madre del músculo esquelético
US9572912B2 (en)	2013-04-19	2017-02-21	Theracell, Inc.	Demineralized bone fibers having controlled geometry and shapes and methods thereof
WO2015070076A2 (fr) *	2013-11-08	2015-05-14	President And Fellows Of Harvard College	Procédés et compositions permettant de régénérer des jonctions neuromusculaires
WO2015073396A1 (fr)	2013-11-12	2015-05-21	The Brigham And Women's Hospital, Inc.	Facteur de croissance et de différenciation (gdf) pour le traitement de l'insuffisance cardiaque diastolique
US10610366B2 (en)	2015-01-29	2020-04-07	Theracell, Inc.	Demineralized bone fiber composition for use in minimally invasive surgery
KR20170138436A (ko)	2015-03-17	2017-12-15	이스티튜토 바이오키미코 이탈리아노 지오바니 로렌치니 에스.피.에이.	골 형성 단백질 (bpm)의 정제
EP3834816A1 (fr)	2015-06-17	2021-06-16	Warsaw Orthopedic, Inc.	Implants comprenant un oxystérol et procédés d'utilisation
EP3821880A1 (fr)	2015-10-26	2021-05-19	President and Fellows of Harvard College	Polysaccharides oxydés et leurs méthodes d'utilisation
CA3010799A1 (fr)	2016-01-06	2017-07-13	President And Fellows Of Harvard College	Un traitement par le gdf11 previent la prise de poids, ameliore la tolerance au glucose, et diminue la steatose hepatique
KR101810385B1 (ko) *	2016-02-04	2017-12-20	주식회사 강스템바이오텍	Gdf11을 포함하는 조성물 및 그의 용도
US10688222B2 (en)	2016-11-21	2020-06-23	Warsaw Orthopedic, Inc.	Lyophilized moldable implants containing an oxysterol
US10639157B2 (en)	2017-03-14	2020-05-05	Theracell, Inc.	Demineralized bone fiber composition for use in minimally invasive surgery
US11464888B2 (en)	2017-06-12	2022-10-11	Warsaw Orthopedic, Inc.	Moldable formulations containing an oxysterol in an acellular tissue matrix
AU2018313306B2 (en)	2017-08-11	2024-06-13	Arteriocyte Medical Systems, Inc.	Demineralized bone fiber composition for augmentation of fixation
KR101893339B1 (ko) *	2017-09-19	2018-08-31	주식회사 강스템바이오텍	Gdf11을 포함하는 조성물 및 그의 용도
US11103618B2 (en)	2018-02-22	2021-08-31	Warsaw Orthopedic, Inc.	Demineralized bone matrix having improved handling characteristics
CN109097425B (zh) *	2018-08-28	2022-06-07	浙江康嘉基因技术有限公司	一种多肽及用作流感疫苗免疫佐剂的用途
US11660373B2 (en)	2019-02-09	2023-05-30	Tetrous, Inc.	Demineralized bone fiber implant compositions and methods for rotator cuff and ACL repair
US11498880B2 (en)	2019-07-26	2022-11-15	Warsaw Orthopedic, Inc.	Calcium phosphate granules and methods of making them

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
DE3382562D1 (de)	1982-09-24	1992-06-25	Us Health	Wiederherstellung von gewebe bei tieren.
US4588684A (en)	1983-04-26	1986-05-13	Chiron Corporation	a-Factor and its processing signals
NZ210699A (en)	1984-01-04	1989-06-28	Int Genetic Eng	Isolation of an osteogenic protein of the p3 immunologically related family
ZA848495B (en)	1984-01-31	1985-09-25	Idaho Res Found	Production of polypeptides in insect cells
CA1341617C (fr)	1984-06-08	2011-06-28	Henry George Burger	Inhibine extracte de liquide folliculaire ovarien
UA39161C2 (uk)	1984-07-06	2001-06-15	Новартіс Аг	Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують
EP0169016B2 (fr)	1984-07-16	2004-04-28	Celtrix Pharmaceuticals, Inc.	Facteur polypeptidique issu des os induisant le cartilage
EP0177343B1 (fr)	1984-10-05	1992-07-22	Genentech, Inc.	ADN, cultures de cellules et méthodes pour sécréter des protéines hétérologiques et récupérer des protéines périplasmiques
US4740587A (en) *	1985-07-18	1988-04-26	The Salk Institute For Biological Studies	Inhibin and method of purifying same
NZ217727A (en) *	1985-10-03	1990-05-28	Genentech Inc	Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US4798885A (en)	1986-02-07	1989-01-17	Genentech, Inc.	Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US5215893A (en) *	1985-10-03	1993-06-01	Genentech, Inc.	Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5089396A (en) *	1985-10-03	1992-02-18	Genentech, Inc.	Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4737578A (en) *	1986-02-10	1988-04-12	The Salk Institute For Biological Studies	Human inhibin
US5108922A (en)	1986-07-01	1992-04-28	Genetics Institute, Inc.	DNA sequences encoding BMP-1 products
US5187076A (en) *	1986-07-01	1993-02-16	Genetics Institute, Inc.	DNA sequences encoding BMP-6 proteins
ZA874681B (en)	1986-07-01	1988-04-27	Genetics Inst	Novel osteoinductive factors
US5013649A (en)	1986-07-01	1991-05-07	Genetics Institute, Inc.	DNA sequences encoding osteoinductive products
US5106748A (en)	1986-07-01	1992-04-21	Genetics Institute, Inc.	Dna sequences encoding 5 proteins
IL83003A (en) *	1986-07-01	1995-07-31	Genetics Inst	Osteoinductive factors
US5041538A (en) *	1987-08-28	1991-08-20	The Salk Institute For Biological Studies	Mammalian follistatin
US5168150A (en)	1988-03-17	1992-12-01	Electronique Serge Dassault	Device for the processing of a magnetic-track ticket, especially an air transport ticket
US5071834A (en)	1988-09-16	1991-12-10	Genentech, Inc.	Purified activin B composition
US5166190A (en) *	1990-01-08	1992-11-24	Genentech, Inc.	Method for increasing fertility in males
WO1991018098A1 (fr)	1990-05-16	1991-11-28	Genetics Institute, Inc.	Proteines d'induction osseuse et cartilagineuse
US5168050A (en) *	1990-05-24	1992-12-01	Genentech, Inc.	Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
EP0550625B1 (fr) *	1990-09-26	2003-11-05	Genetics Institute, LLC	Derives bmp-5
WO1992009697A1 (fr) *	1990-11-30	1992-06-11	Celtrix Laboratories, Inc.	UTILISATION EN OSTEOPATHIE D'UNE PROTEINE MORPHOGENETIQUE D'ORIGINE OSSEUSE ASSOCIEE DE MANIERE SYNERGIQUE AVEC DU BETA DE FACTEUR DE CROISSANCE DE TRANSFORMATION (β-FCT).
US5208219A (en) *	1991-02-14	1993-05-04	Celtrix Pharmaceuticals Inc.	Method for inducing bone growth
WO1992020371A1 (fr) *	1991-05-10	1992-11-26	Celtrix Pharmaceuticals, Inc.	Apport cible de facteurs de croissance osseuse
EP0592562B1 (fr) *	1991-06-25	1999-01-07	Genetics Institute, Inc.	Compositions bmp-9
US5171579A (en) *	1991-10-11	1992-12-15	Genetics Institute, Inc.	Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
WO1993009229A1 (fr) *	1991-11-04	1993-05-13	Genetics Institute, Inc.	Proteines heterodimeres morphogenetiques d'os de recombinaison, compositions et procedes d'utilisation
PT653942E (pt)	1992-07-31	2003-11-28	Curis Inc	Regeneracao e reparacao de nervos induzidos por morfogenios
DK0690873T3 (da) *	1993-03-19	2003-09-29	Univ Johns Hopkins Med	Vækstdifferentieringsfaktor-8
WO1994026892A1 (fr) *	1993-05-12	1994-11-24	Genetics Institute, Inc.	Compositions de bmp-11
JPH09501305A (ja) *	1993-05-12	1997-02-10	ジェネティックス・インスティテュート・インコーポレイテッド	Ｂｍｐ−１０組成物
EP1716864A1 (fr) *	1993-08-26	2006-11-02	Genetics Institute, LLC	Régéneration nerveuse utilisant des protéines morphogénetiques osseuses chez l'homme
EP1574577A3 (fr) *	1994-07-08	2006-06-14	The Johns Hopkins University School Of Medicine	Facteur 11 de differentation de croissance
US5545616A (en) *	1994-09-22	1996-08-13	Genentech, Inc.	Method for predicting and/or preventing preterm labor
EP0894004B2 (fr)	1996-03-22	2007-02-21	Curis, Inc.	Procede pour favoriser la recuperation fonctionnelle de la coordination motrice, de la parole ou de la perception sensorielle a la suite d'une ischemie ou d'un traumatisme du systeme nerveux central
JP3361278B2 (ja)	1997-12-26	2003-01-07	シャープ株式会社	反射型液晶表示装置とその製造方法、ならびに回路基板の製造方法
US6004937A (en) *	1998-03-09	1999-12-21	Genetics Institute, Inc.	Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]

1994
- 1994-05-12 WO PCT/US1994/005288 patent/WO1994026892A1/fr not_active Ceased
- 1994-05-12 CA CA002161808A patent/CA2161808C/fr not_active Expired - Fee Related
- 1994-05-12 PT PT03021107T patent/PT1378572E/pt unknown
- 1994-05-12 PT PT94917361T patent/PT698094E/pt unknown
- 1994-05-12 DK DK03021107T patent/DK1378572T3/da active
- 1994-05-12 AT AT94917361T patent/ATE258984T1/de active
- 1994-05-12 DK DK94917361T patent/DK0698094T3/da active
- 1994-05-12 ES ES03021107T patent/ES2274157T3/es not_active Expired - Lifetime
- 1994-05-12 AU AU69105/94A patent/AU678582B2/en not_active Ceased
- 1994-05-12 JP JP52569894A patent/JP3681069B2/ja not_active Expired - Fee Related
- 1994-05-12 EP EP94917361A patent/EP0698094B1/fr not_active Expired - Lifetime
- 1994-05-12 EP EP10181708A patent/EP2272959A1/fr not_active Withdrawn
- 1994-05-12 EP EP06022258A patent/EP1770161A3/fr not_active Withdrawn
- 1994-05-12 ES ES94917361T patent/ES2213745T3/es not_active Expired - Lifetime
- 1994-05-12 EP EP03021107A patent/EP1378572B1/fr not_active Expired - Lifetime
- 1994-05-12 BR BR9406715A patent/BR9406715A/pt not_active Application Discontinuation
- 1994-05-12 DE DE69434875T patent/DE69434875T2/de not_active Expired - Lifetime
- 1994-05-12 DE DE69433530T patent/DE69433530T2/de not_active Expired - Lifetime
- 1994-05-12 AT AT03021107T patent/ATE343635T1/de active
- 1994-05-12 KR KR1019950704836A patent/KR100227406B1/ko not_active Expired - Fee Related
- 1994-05-20 US US08/247,907 patent/US5639638A/en not_active Expired - Lifetime
1995
- 1995-05-30 US US08/452,772 patent/US5700911A/en not_active Expired - Lifetime
- 1995-11-08 NO NO19954492A patent/NO320119B1/no not_active IP Right Cessation
- 1995-11-10 OA OA60735A patent/OA10191A/en unknown
- 1995-11-10 FI FI955419A patent/FI119696B/fi not_active IP Right Cessation
1997
- 1997-08-28 US US08/919,850 patent/US6437111B1/en not_active Expired - Fee Related
1999
- 1999-10-07 US US09/414,234 patent/US6340668B1/en not_active Expired - Fee Related
2001
- 2001-12-20 US US10/029,016 patent/US20030083252A1/en not_active Abandoned
2002
- 2002-07-05 US US10/188,886 patent/US7175997B2/en not_active Expired - Fee Related
2004
- 2004-08-24 JP JP2004243948A patent/JP2005046155A/ja active Pending
2006
- 2006-04-11 US US11/401,228 patent/US20060172391A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1378572E (pt)	2007-01-31
ES2274157T3 (es)	2007-05-16
US20030083252A1 (en)	2003-05-01
HK1060898A1 (en)	2004-08-27
NO954492D0 (no)	1995-11-08
FI955419L (fi)	1996-01-08
US5700911A (en)	1997-12-23
CA2161808C (fr)	2008-08-05
ATE258984T1 (de)	2004-02-15
EP0698094A1 (fr)	1996-02-28
JP3681069B2 (ja)	2005-08-10
EP1378572A1 (fr)	2004-01-07
FI955419A0 (fi)	1995-11-10
US20030166910A1 (en)	2003-09-04
DE69433530T2 (de)	2005-01-05
US7175997B2 (en)	2007-02-13
BR9406715A (pt)	1996-02-06
OA10191A (en)	1996-12-18
JPH09501304A (ja)	1997-02-10
ATE343635T1 (de)	2006-11-15
EP0698094B1 (fr)	2004-02-04
JP2005046155A (ja)	2005-02-24
EP2272959A1 (fr)	2011-01-12
AU678582B2 (en)	1997-06-05
WO1994026892A1 (fr)	1994-11-24
CA2161808A1 (fr)	1994-11-24
DE69434875T2 (de)	2007-09-06
EP1770161A3 (fr)	2008-04-23
DK0698094T3 (da)	2004-05-03
DE69433530D1 (de)	2004-03-11
PT698094E (pt)	2004-05-31
DK1378572T3 (da)	2007-02-05
AU6910594A (en)	1994-12-12
NO954492L (no)	1995-11-08
FI119696B (fi)	2009-02-13
KR960701996A (ko)	1996-03-28
DE69434875D1 (de)	2006-12-07
EP1378572B1 (fr)	2006-10-25
KR100227406B1 (ko)	1999-12-01
US6437111B1 (en)	2002-08-20
US5639638A (en)	1997-06-17
US20060172391A1 (en)	2006-08-03
US6340668B1 (en)	2002-01-22
EP1770161A2 (fr)	2007-04-04
ES2213745T3 (es)	2004-09-01

Legal Events

Date	Code	Title	Description
2013-12-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US7175997B2 (en)	2007-02-13	BMP-11 compositions
EP0698095B1 (fr)	2004-04-28	Compositions de bmp-10
US5637480A (en)	1997-06-10	DNA molecules encoding bone morphogenetic protein-10
CA2265508C (fr)	2003-11-18	Compositions de proteines-16 morphogenetiques osseuses
US6492493B2 (en)	2002-12-10	Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
WO1996036710A1 (fr)	1996-11-21	Compositions de proteines bmp-15
WO1999024057A2 (fr)	1999-05-20	Utilisations neuronales de bmp-11
OA10987A (en)	2003-03-04	A game-type flavouring agent
CA2574929C (fr)	2011-08-23	Proteine morphogenetique osseuse (bmp)-17 et bmp-18 et compositions
AU763300B2 (en)	2003-07-17	Bone morphogenetic protein-16 (BMP-16) compositions
HK1060898B (en)	2006-12-29	Bmp-11 compositions
MXPA00004347A (en)	2001-05-17	Neuronal uses of bmp-11